Close Menu
October 08, 2020
Sponsored by
Thermo Fisher Scientific

Optimized Protocol for Sequencing the SARS-CoV-2 Genome

Case Study

Join or Log in for Access

This content is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Strain identification and study of viral evolution is made more accurate by a workflow offered by Invitrogen for the study of SARS-CoV-2 and other viruses. The workflow is designed for flexibility to accommodate shifts in availability of components while providing strong viral coverage for sensitive SNP detection. In this eCase Study, Cris Kinross will give an overview of the workflow, demonstrate the coverage and variant detection achieved, and provide a link to the full optimized protocol

Sponsored by

The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.

Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.

The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.

In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.

Mar
11
Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar
17
Sponsored by
IONPath

In this webinar, Felix J. Hartmann of Stanford University will describe an approach that characterizes the metabolic regulome of individual cells together with their phenotypic identity.

Mar
18
Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.

Mar
25
Sponsored by
Foundation Medicine

In this session, the fourth in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling identified no clear molecular markers to help guide personalized therapy.